Novo Nordisk is facing a proposed nationwide class action lawsuit that alleges inadequate warning about severe side effects, including stomach paralysis linked to the drug.

The study, published in JAMA, found these adverse gastrointestinal effects happen in non-diabetic patients using the drugs specifically for weight loss.